dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Sablin, Marie-Paule |
dc.contributor.author | Bergh, Jonas |
dc.contributor.author | Im, Seock-Ah |
dc.contributor.author | Lu, Yen-Shen |
dc.contributor.author | Martínez, Noelia |
dc.contributor.author | Cortés Castan, Javier |
dc.contributor.author | Schmid, Peter |
dc.date.accessioned | 2021-06-29T10:09:04Z |
dc.date.available | 2021-06-29T10:09:04Z |
dc.date.issued | 2021-01-15 |
dc.identifier.citation | Schmid P, Sablin MP, Bergh J, Im SA, Lu YS, Martínez N, et al. A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. Breast Cancer Res. 2021 Jan 15;23:8. |
dc.identifier.issn | 1465-542X |
dc.identifier.uri | https://hdl.handle.net/11351/6097 |
dc.description | Càncer de mama; HER2-negatiu; Receptor hormonal positiu |
dc.description.sponsorship | This work was supported by Boehringer Ingelheim International GmbH. |
dc.language.iso | eng |
dc.publisher | BMC |
dc.relation.ispartofseries | Breast Cancer Research;23 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Medicaments - Eficàcia |
dc.subject | Mama - Càncer - Tractament |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | Drug Therapy, Combination |
dc.subject.mesh | Treatment Outcome |
dc.title | A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1186/s13058-020-01382-8 |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | farmacoterapia combinada |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-020-01382-8 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Schmid P] Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK. [Sablin MP] Department of Drug Development and Innovation, Institut Curie, Paris, France. [Bergh J] Department of Oncology-Pathology, Karolinska Institutet and Breast Cancer Centre, Cancer Theme, Karolinska University Hospital, Stockholm, Sweden. [Im SA] Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea. [Lu YS] Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. [Martínez N] Department of Oncology, Ramon y Cajal University Hospital, Madrid, Spain. [Cortés J] Breast Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Department of Oncology, IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain |
dc.identifier.pmid | 33451345 |
dc.identifier.wos | 000608053300001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |